突然杀回来了！创新药ETF大盘点！

格隆汇04-04

萎靡7个月的创新药，突然杀回来了！成为美伊冲突以来，仅次于能源板块的亮眼存在。截至4月3日，美伊冲突以来，ETF指数涨幅TOP30榜单里，一半以上被创新药包场，恒生创新药、恒生港股通创新药精选、恒生港股通创新药、科创新药涨超9%。(本文内容均为客观数据信息罗列，不构成任何投资建议）创新药为何能在风声鹤唳的地缘冲突期间脱颖而出？首先，“924”以来，市场连续两年靠拔估值上涨，但历史上还没有出现过连续...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2624695134?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/a0989-a422cedf-f15d-459f-90fa-e7074c8daf48.jpg?guru_height=2241&guru_width=3280&guru_size=1441563","is_english":false,"pubTime":"2026-04-04 11:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624695134","market":"hk","top_or_hot":-1,"title":"突然杀回来了！创新药ETF大盘点！","media":"格隆汇","content":"<div>\n<p>萎靡7个月的创新药，突然杀回来了！成为美伊冲突以来，仅次于能源板块的亮眼存在。截至4月3日，美伊冲突以来，ETF指数涨幅TOP30榜单里，一半以上被创新药包场，恒生创新药、恒生港股通创新药精选、恒生港股通创新药、科创新药涨超9%。(本文内容均为客观数据信息罗列，不构成任何投资建议）创新药为何能在风声鹤唳的地缘冲突期间脱颖而出？首先，“924”以来，市场连续两年靠拔估值上涨，但历史上还没有出现过连续...</p>\n\n<a href=\"https://www.gelonghui.com/p/4307632\">网页链接</a>\n\n</div>\n","source":"gelonghui_fund_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>突然杀回来了！创新药ETF大盘点！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n突然杀回来了！创新药ETF大盘点！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-04 11:35 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/4307632><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>萎靡7个月的创新药，突然杀回来了！成为美伊冲突以来，仅次于能源板块的亮眼存在。截至4月3日，美伊冲突以来，ETF指数涨幅TOP30榜单里，一半以上被创新药包场，恒生创新药、恒生港股通创新药精选、恒生港股通创新药、科创新药涨超9%。(本文内容均为客观数据信息罗列，不构成任何投资建议）创新药为何能在风声鹤唳的地缘冲突期间脱颖而出？首先，“924”以来，市场连续两年靠拔估值上涨，但历史上还没有出现过连续...</p>\n\n<a href=\"https://www.gelonghui.com/p/4307632\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1500","symbol_name":"做空集合股","start_time":0,"source_url":"https://www.gelonghui.com/p/4307632","article_id":"2624695134","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/a0989-a422cedf-f15d-459f-90fa-e7074c8daf48.jpg?guru_height=2241&guru_width=3280&guru_size=1441563"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624695134","pubTimestamp":1775273728,"columns":[],"sourceInfo":{"source_id":"gelonghui_fund_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"图解创新药主题ETF","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1500":"做空集合股","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","BK1574":"生物医药B类股","BK1161":"生物科技","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","06978":"永泰生物-B","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","BK1588":"回港中概股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","06160":"百济神州"},"translate_title":"Suddenly killed back! Innovative Drug ETF Inventory!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":0.9,"06978":0.9},"content_text":"萎靡7个月的创新药，突然杀回来了！成为美伊冲突以来，仅次于能源板块的亮眼存在。截至4月3日，美伊冲突以来，ETF指数涨幅TOP30榜单里，一半以上被创新药包场，恒生创新药、恒生港股通创新药精选、恒生港股通创新药、科创新药涨超9%。(本文内容均为客观数据信息罗列，不构成任何投资建议）创新药为何能在风声鹤唳的地缘冲突期间脱颖而出？首先，“924”以来，市场连续两年靠拔估值上涨，但历史上还没有出现过连续3年“提估值”的情况，因此盈利改善是今年市场跟踪焦点之一。近些年来，中国上市公司盈利改善出现明显的新旧交替变化，从以往的地产、基建、消费转向科技、以及出海。创新药，恰恰是今年盈利改善最明显的方向之一。去年9月达到高位后持续回调的创新药板块，迎来了BD出海强劲和亮眼的财报数据两大关键催化剂。国家药监局数据显示，今年一季度，创新药对外授权（License-out）交易总额超过600亿美元，接近2025年全年的一半。此外，国际药企愿意先付更多钱了。中信证券数据显示，一季度创新药授权出海的首付款同比暴增229%，表明全球对中国创新药的认可。2025年年报数据显示，百济神州、信达生物、诺诚健华、云顶新耀、中国生物医药等扭亏转盈，恒瑞医药创新药收入占比突破58%。目前A股与创新药主题相关的指数高达19只，如：国证港股通创新药、恒生港股通创新药：追求极致纯度的港股创新药工具，最大的标签是 “纯”，最新指数编制修订彻底剔除了CXO公司，创新药含量100%。港股创新药CNY：同时涵盖了创新药企和CXO服务商，全面地反映了港股创新药生态的整体表现。恒生生物科技指数：聚焦港股生物科技龙头的旗舰指数，选取港股通内市值最大的30家生物科技公司，是龙头属性最强的指数。成份股不仅包括百济神州、信达生物等创新药巨头，也包含药明生物等CXO龙头，以及京东健康等医药分销公司，范围更广。CS创新药：A股市场最具代表性的创新药指数，不仅包括恒瑞医药、百济神州（A股）等创新药企，也包含了药明康德、泰格医药等CXO龙头，是覆盖创新药全产业链的“集合体”。科创新药：科创板内高纯度、高成长创新药公司集合，成份股包括百济神州、艾力斯、百利天恒，小市值、成长型属性鲜明，涨跌幅限制为20%，弹性天然高于其他创新药指数。从近两年业绩来看，中证港股通创新药、国证港股通创新药、恒生港股通创新药精选、港股创新药CNY涨幅居前，均涨超100%。目前规模超百亿的创新药主题ETF有三只：港股通创新药ETF汇添富(159570)、港股创新药ETF广发(513120)和创新药ETF银华(159992)。综合费率处于0.2%最低一档的创新药ETF有5只：跟踪国证港股通创新药指数：港股通创新药ETF南方(159297)跟踪CS创新药指数：创新药ETF易方达(516080)、创新药ETF南方(159858)跟踪恒生生物科技：恒生生物科技ETF汇添富(513280)跟踪恒生港股通创新药：港股通创新药ETF易方达(159316)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624695134","isCrawlerRequest":true}